Literature DB >> 18479894

Role of Stat3 in suppressing anti-tumor immunity.

Marcin Kortylewski1, Hua Yu.   

Abstract

Recent evidence suggests that what sustains a tumor's survival and proliferation can also subvert the immune system from its defense role. As a point of convergence for numerous oncogenic signaling pathways, Stat3 is constitutively activated in diverse human cancer cells. Activated Stat3 not only upregulates genes crucial for survival, proliferation, angiogenesis, and metastasis but also promotes expression of immune suppressive factors while inhibiting Th1 immunostimulatory molecules. By virtue of its ability to promote expression of many factors that activate Stat3 in diverse cells, Stat3 allows malignant and immune cells resonate, forming close partnership for tumor immune evasion, tumor progression, and resistance to therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18479894      PMCID: PMC2488961          DOI: 10.1016/j.coi.2008.03.010

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  50 in total

Review 1.  Th17: an effector CD4 T cell lineage with regulatory T cell ties.

Authors:  Casey T Weaver; Laurie E Harrington; Paul R Mangan; Maya Gavrieli; Kenneth M Murphy
Journal:  Immunity       Date:  2006-06       Impact factor: 31.745

2.  STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice.

Authors:  Mi-La Cho; Jung-Won Kang; Young-Mee Moon; Hyo-Jung Nam; Joo-Yeon Jhun; Seong-Beom Heo; Hyun-Tak Jin; So-Youn Min; Ji-Hyeon Ju; Kyung-Su Park; Young-Gyu Cho; Chong-Hyeon Yoon; Sung-Hwan Park; Young-Chul Sung; Ho-Youn Kim
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

3.  IL-23 promotes tumour incidence and growth.

Authors:  John L Langowski; Xueqing Zhang; Lingling Wu; Jeanine D Mattson; Taiying Chen; Kathy Smith; Beth Basham; Terrill McClanahan; Robert A Kastelein; Martin Oft
Journal:  Nature       Date:  2006-05-10       Impact factor: 49.962

4.  IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo.

Authors:  Emmanuel Zorn; Erik A Nelson; Mehrdad Mohseni; Fabrice Porcheray; Haesook Kim; Despina Litsa; Roberto Bellucci; Elke Raderschall; Christine Canning; Robert J Soiffer; David A Frank; Jerome Ritz
Journal:  Blood       Date:  2006-04-27       Impact factor: 22.113

5.  Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3.

Authors:  Monika Kasprzycka; Michal Marzec; Xiaobin Liu; Qian Zhang; Mariusz A Wasik
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-09       Impact factor: 11.205

6.  Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells.

Authors:  Jinwei Hu; Xiangpeng Yuan; Maria L Belladonna; John M Ong; Sebastian Wachsmann-Hogiu; Daniel L Farkas; Keith L Black; John S Yu
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

7.  Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells.

Authors:  Zhi Chen; Arian Laurence; Yuka Kanno; Margit Pacher-Zavisin; Bing-Mei Zhu; Cristina Tato; Akihiko Yoshimura; Lothar Hennighausen; John J O'Shea
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-12       Impact factor: 11.205

8.  Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Authors:  Jérôme Galon; Anne Costes; Fatima Sanchez-Cabo; Amos Kirilovsky; Bernhard Mlecnik; Christine Lagorce-Pagès; Marie Tosolini; Matthieu Camus; Anne Berger; Philippe Wind; Franck Zinzindohoué; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

9.  The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells.

Authors:  Hidetoshi Sumimoto; Fumie Imabayashi; Tomoko Iwata; Yutaka Kawakami
Journal:  J Exp Med       Date:  2006-06-26       Impact factor: 14.307

10.  Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1.

Authors:  Ichiko Kinjyo; Hiromasa Inoue; Shinjiro Hamano; Satoru Fukuyama; Takeru Yoshimura; Keiko Koga; Hiromi Takaki; Kunisuke Himeno; Giichi Takaesu; Takashi Kobayashi; Akihiko Yoshimura
Journal:  J Exp Med       Date:  2006-04-10       Impact factor: 14.307

View more
  78 in total

1.  STAT3 Knockdown in B16 Melanoma by siRNA Lipopolyplexes Induces Bystander Immune Response In Vitro and In Vivo.

Authors:  Aws Alshamsan; Samar Hamdy; Azita Haddadi; John Samuel; Ayman O S El-Kadi; Hasan Uludağ; Afsaneh Lavasanifar
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

2.  p38 Mitogen-activated protein kinase/signal transducer and activator of transcription-3 pathway signaling regulates expression of inhibitory molecules in T cells activated by HIV-1-exposed dendritic cells.

Authors:  Karlhans Fru Che; Esaki Muthu Shankar; Sundaram Muthu; Sasan Zandi; Mikael Sigvardsson; Jorma Hinkula; Davorka Messmer; Marie Larsson
Journal:  Mol Med       Date:  2012-10-24       Impact factor: 6.354

Review 3.  Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.

Authors:  Tim F Greten; Xin W Wang; Firouzeh Korangy
Journal:  Gut       Date:  2015-02-09       Impact factor: 23.059

4.  Extracellular hepatitis C virus core protein activates STAT3 in human monocytes/macrophages/dendritic cells via an IL-6 autocrine pathway.

Authors:  Robert S Tacke; Annie Tosello-Trampont; Virginia Nguyen; David W Mullins; Young S Hahn
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

5.  Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis.

Authors:  Cesar E Ochoa; Seyedeh Golsar Mirabolfathinejad; Venado Ana Ruiz; Scott E Evans; Mihai Gagea; Christopher M Evans; Burton F Dickey; Seyed Javad Moghaddam
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-22

Review 6.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

7.  Migration or evasion.

Authors:  Cornelis Melief
Journal:  Nat Med       Date:  2010-01       Impact factor: 53.440

Review 8.  Lymphocytes in cancer development: polarization towards pro-tumor immunity.

Authors:  Brian Ruffell; David G DeNardo; Nesrine I Affara; Lisa M Coussens
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-11       Impact factor: 7.638

9.  In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses.

Authors:  Marcin Kortylewski; Piotr Swiderski; Andreas Herrmann; Lin Wang; Claudia Kowolik; Maciej Kujawski; Heehyoung Lee; Anna Scuto; Yong Liu; Chunmei Yang; Jiehui Deng; Harris S Soifer; Andrew Raubitschek; Stephen Forman; John J Rossi; Drew M Pardoll; Richard Jove; Hua Yu
Journal:  Nat Biotechnol       Date:  2009-09-13       Impact factor: 54.908

10.  yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients.

Authors:  William Humphries; Yongtao Wang; Wei Qiao; Chantal Reina-Ortiz; Mohamed K Abou-Ghazal; Lamonne M Crutcher; Jun Wei; Ling-Yuan Kong; Raymond Sawaya; Ganesh Rao; Jeffrey Weinberg; Sujit S Prabhu; Gregory N Fuller; Amy B Heimberger
Journal:  J Transl Med       Date:  2009-11-09       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.